Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
[ X ]
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Baishideng Publishing Group Inc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
BACKGROUND Refractory pouchitis is a common cause of pouch failure, which may require surgical excision of the pouch or permanent diversion. We aimed to show the effect of vedolizumab on treatment of the patient with refractory pouchitis. CASE SUMMARY A 32-year-old male with pancolonic ulcerative colitis since the age of 25 with primary failure of infliximab and mesalamine and intolerance of azathioprine, underwent a total proctocolectomy with ileal pouch-anal anastomosis in 2012. He developed chronic diarrhea in 2014, which was watery, 30 per day and accompanied with blood and mucus affecting his quality of life. CONCLUSION Vedolizumab is safe and effective in the management of anti-tumor necrosis factor alpha refractory pouchitis.
Açıklama
Anahtar Kelimeler
Anti-tumor necrosis factor alpha, Refractory pouchitis, Vedolizumab, Ulcerative colitis
Kaynak
World Journal of Clinical Cases
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
7
Sayı
16
